Figure 4. LPS treatments also alter cell content in the bone marrow of P2Y₁₂ KO mice.

Cells isolated from the bone marrow were analyzed, and graphs show neutrophil (A) and lymphocyte (B) count in WT (black) and P2Y₁₂ KO mice (white) for control, clopidogrel, LPS, and LPS plus clopidogrel. *P < 0.01 and **P < 0.05 treated versus untreated and WT versus KO (n=6). (C) Representative flow cytometry histograms (left) showing CD11b, CD25, and CD69 staining in WT, KO, WT plus clopidogrel, and KO plus clopidogrel of LPS-treated (black line) and untreated (gray line) bone marrow samples. GMFI values of WT (black bars) and KO (white bars) are plotted on the right. *P < 0.01 and **P < 0.05 treated versus untreated and WT versus KO (n=6). Isotype controls were 7.5 ± 0.3 for PE-labeled (CD11b), 84 ± 9 for APC-labeled (CD25), and 28 ± 6 for APC-labeled (CD69). (D) Percentage values of CD11b⁺CD14⁺ cells in WT (black bars) and KO (white bars) are plotted for controls, clopidogrel, LPS, and LPS plus clopidogrel animals analyzed in WT and KO (n=6). Negative control was 5 ± 1%.